Determination of HCV genotypes and viral loads in chronic hepatic Sudanese infected patients

  • Mohammed E. H. Ournasseir
Keywords: Hepatitis C virus, genotypes, viral loads, chronic hepatic

Abstract

Background. Knowledge of Hepatitis C virus (HCV) genotypes is significant for arranging treatment regimes. Quantitative HCV RNA testing provides prognostic data useful in monitoring the efficacy of antiviral therapy.

Methods. A total of 1203 serum samples were collected from individuals attending out-patients units at Khartoum State and Gezera State. The study population comprises two groups. Blood donors study groups (n= 600) and chronic hepatic patients during the course of HCV infection (n= 603). Serum samples were screened using enzyme linked immune-sorbent assay (ELISA) (Biokit, A.S. Spain®).HCV positive samples (n=100) were quantified by HCV Real-TM Quant SC (Sacace Biotechnologies Italy®).

Results: Hundred HCV seropositive samples were subjected to genotyping and quantitative analysis of these samples using RT- PCR, HCV genotype 4 was the predominant genotype (92%) followed by genotype 2 (4%), Genotype 1 (2%) and 3 (2%) in different groups. The average viral load of the patients infected with genotype 4 was higher than an average viral load of the patients infected with genotypes 1,2 and 3.

Conclusions: The present study highlighted that genotype 4 is the predominant genotype in Sudanese hepatic patients followed by genotype 2. The severity of liver disease was more among genotype 4 patients as assessed by a higher viral load.

References

1. Kuo, G., et al., An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 1989. 244(4902): p. 362-4.
2. Zein, N.N., Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev, 2000. 13(2): p. 223-35.
3. Larke, B., et al., Acute nosocomial HCV infection detected by NAT of a regular blood donor. Transfusion, 2002. 42(6): p. 759-65.
4. Pearlman, B.L., Hepatitis C infection: a clinical review. South Med J, 2004. 97(4): p. 364-73; quiz 374.
5. Sarbah, S.A., et al., Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci, 2004. 49(5): p. 850-3.
6. Bradley, J.S., et al., Prevalence of hepatitis C virus antibody in newborn infants in southern California in 2003. Pediatr Infect Dis J, 2011. 30(7): p. 618-20.
7. Bradley, D.W., Studies of non-A, non-B hepatitis and characterization of the hepatitis C virus in chimpanzees. Curr Top Microbiol Immunol, 2000. 242: p. 1-23.
8. Aach, R.D., R.A. Yomtovian, and M. Hack, Neonatal and pediatric posttransfusion hepatitis C: a look back and a look forward. Pediatrics, 2000. 105(4 Pt 1): p. 836-42.
9. Daniel, H.D., et al., Quantitation of hepatitis C virus using an in-house real-time reverse transcriptase polymerase chain reaction in plasma samples. Diagn Microbiol Infect Dis, 2008. 61(4): p.
415-20.
10. Smith, D.B., et al., A second outbreak of hepatitis C virus infection from anti-D immunoglobulin in Ireland. Vox Sang, 1999. 76(3): p. 175-80.
Published
2019-12-31